File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia

TitleSolid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia
Authors
Au, WYKumana, CRLam, CWCheng, VCCShek, TWChan, EYTLiu, RKwong, YL
KeywordsArsenic trioxide
Colonic carcinoma
Nasopharyngeal carcinoma
Issue Date2007
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukres
Citation
Leukemia Research, 2007, v. 31 n. 1, p. 105-108 How to Cite?
DOI: http://dx.doi.org/10.1016/j.leukres.2006.03.018
AbstractArsenic trioxide (As 2O 3) is highly efficacious for acute promyelocytic leukemia (APL). Environmental arsenic exposure predisposes to malignancies, but the risk for therapeutic arsenic is undefined. Three APL patients (de novo, 2; therapy-related, 1) in a cohort of 59 cases given oral-As 2O 3 for induction and maintenance treatment developed secondary cancers (nasopharyngeal carcinoma, 2; colonic adenocarcinoma, 1) at 16, 36 and 55 months post-As 2O 3 therapy. Retrospective analysis of biomarkers (Epstein Barr virus serology and quantification, carcinoembryonic antigen) showed the potential presence of cancers before or shortly after As 2O 3 therapy, suggesting that As 2O 3 had not initiated these malignancies. Compared against matched background population, there was an increased risk of second cancer (p = 0.012, standard incidence ratio = 6.5; 95% confidence interval = 1.4-19.0). © 2006 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/77714
ISSN
0145-2126
2023 Impact Factor: 2.1
2023 SCImago Journal Rankings: 0.694
ISI Accession Number ID
WOS:000242797900017
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorKumana, CRen_HK
dc.contributor.authorLam, CWen_HK
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorShek, TWen_HK
dc.contributor.authorChan, EYTen_HK
dc.contributor.authorLiu, Ren_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:34:55Z-
dc.date.available2010-09-06T07:34:55Z-
dc.date.issued2007en_HK
dc.identifier.citationLeukemia Research, 2007, v. 31 n. 1, p. 105-108en_HK
dc.identifier.issn0145-2126en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77714-
dc.description.abstractArsenic trioxide (As 2O 3) is highly efficacious for acute promyelocytic leukemia (APL). Environmental arsenic exposure predisposes to malignancies, but the risk for therapeutic arsenic is undefined. Three APL patients (de novo, 2; therapy-related, 1) in a cohort of 59 cases given oral-As 2O 3 for induction and maintenance treatment developed secondary cancers (nasopharyngeal carcinoma, 2; colonic adenocarcinoma, 1) at 16, 36 and 55 months post-As 2O 3 therapy. Retrospective analysis of biomarkers (Epstein Barr virus serology and quantification, carcinoembryonic antigen) showed the potential presence of cancers before or shortly after As 2O 3 therapy, suggesting that As 2O 3 had not initiated these malignancies. Compared against matched background population, there was an increased risk of second cancer (p = 0.012, standard incidence ratio = 6.5; 95% confidence interval = 1.4-19.0). © 2006 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukresen_HK
dc.relation.ispartofLeukemia Researchen_HK
dc.subjectArsenic trioxideen_HK
dc.subjectColonic carcinomaen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subject.meshAdenocarcinoma - chemically induceden_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshArsenicals - adverse effects - therapeutic useen_HK
dc.subject.meshColonic Neoplasms - chemically induceden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGrowth Inhibitors - adverse effects - therapeutic useen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLeukemia, Promyelocytic, Acute - drug therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshNasopharyngeal Neoplasms - chemically induceden_HK
dc.subject.meshNeoplasms - chemically induceden_HK
dc.subject.meshOxides - adverse effects - therapeutic useen_HK
dc.titleSolid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemiaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0145-2126&volume=31&issue=1&spage=105&epage=108&date=2006&atitle=Solid+tumors+subsequent+to+arsenic+trioxide+treatment+for+acute+promyelocytic+leukemiaen_HK
dc.identifier.emailLam, CW:ching-wanlam@pathology.hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityLam, CW=rp00260en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.leukres.2006.03.018en_HK
dc.identifier.pmid16725199-
dc.identifier.scopuseid_2-s2.0-33750684984en_HK
dc.identifier.hkuros118819en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33750684984&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume31en_HK
dc.identifier.issue1en_HK
dc.identifier.spage105en_HK
dc.identifier.epage108en_HK
dc.identifier.isiWOS:000242797900017-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridKumana, CR=7005112381en_HK
dc.identifier.scopusauthoridLam, CW=34570692600en_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridShek, TW=7005479861en_HK
dc.identifier.scopusauthoridChan, EYT=7401994013en_HK
dc.identifier.scopusauthoridLiu, R=15056333400en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.issnl0145-2126-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats